Manchester Capital Management LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,000 shares of the company’s stock, valued at approximately $63,000. Several other hedge funds and other institutional investors have also […]